Global Nephritis Market, By Type (Glomerulonephritis, Nephropathy, Goodpasture Syndrome, Others), Treatment (Corticosteroids, ACE Inhibitors, Immunosuppressive Therapy, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Nephritis Market Analysis and Size
The global nephritis market is anticipated to witness major growth during the forecast period. According to the CDC reports, more than 37 million people in the U.S. are expected to suffer from chronic kidney disease, whereas globally more than 500 million people are affected. Genetics may also play a role in developing nephritis, such as for chronic glomerulonephritis. For those who may be at higher risk, routine bloodwork and urine testing can be done to look at levels of a compound called creatinine that will reflect kidney function.
Data Bridge Market Research analyses a growth rate in the global nephritis market in the forecast period 2022-2029. The expected CAGR of global nephritis market is tend to be around 5.2% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Nephritis Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Million, Volumes in Units, Pricing in USD
Type (Glomerulonephritis, Nephropathy, Goodpasture Syndrome, Others), Treatment (Corticosteroids, ACE Inhibitors, Immunosuppressive Therapy, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), AbbVie.Inc (U.S.), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Aurobindo Pharma (India), Fresenius SE & Co. KGaA (Germany), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.)
Nephritis is a type of renal disorder affecting the small kidney filtering unit called glomeruli. It is mainly caused by numerous factors such as autoimmune disorders, genetic factors, and infection in other parts of the body and sclerotic diseases. It may be caused by infection, inflammatory conditions, certain genetic conditions, and other diseases or conditions. It can also be caused by taking certain medicines or being exposed to certain chemicals
Global Nephritis Market Dynamics
- Increased Incidence of Kidney Diseases
The increasing prevalence of chronic kidney disease worldwide is majorly responsible for boosting the growth of the global nephritis market. The National Kidney Foundation reports that around 10% of the global population is affected by chronic kidney disease (CKD). As per WHO facts 2019, around 1.13 billion people worldwide have hypertension. In the year 2014–2016, diabetes and hypertension were responsible for approximately 75% of kidney failure. Thus, it boosts the market growth.
- Rising Demand for Oral Drugs
Oral drugs is projected to boost the market growth. The segment is anticipated to expand the global market as most products are available in capsule form and tablet form and it is a very convenient route of administration.
- Rising clinical trials for drug development by several market players
More and more clinical trials are being developed by different market players that are boosting the opportunities for the market. For instance, Felzartamab (MOR202) is a therapeutic human monoclonal antibody derived from MorphoSys’ HuCAL antibody library and directed against CD38. It is currently under phase Ib/IIa trial. The safety and efficacy of Felzartamab are currently investigated in patients with glomerulonephritis, including anti-PLA2R antibody-positive membranous nephropathy (MN) and IgA nephropathy (IgAN), both autoimmune renal diseases. Thus, the market is expected to drive in the forecast period.
- Increasing Demand for Hospitals
The presence of a large number of hospitals in the U.S., along with a well-developed healthcare infrastructure, is another factor contributing to market growth. For instance, as per the American Hospital Association, there were around 6,090 community hospitals, 208 federal government hospitals, and 625 nonfederal psychiatric hospitals in the U.S. Major increase in the number of hospitals and hospital admissions for nephritis is boosting the demand for dialysis as well as transplant, thereby boosting the market growth.
- Side Effects of Renal Drugs
The side effects associated with these renal drugs could curb the growth of the global nephritis market over a forecast period. Effects such as loss of appetite, fever, rashes, can hamper the market growth.
- High Cost
The huge expenditure associated with these agents hamper the market growth. Treatments that include corticosteroids, diuretics, immunosuppressive therapy, ACE inhibitors, impede the growth of the market.
This global nephritis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global nephritis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Nephritis Market
The growing cases of COVID-19 directly correlate with the growth of kidney-related diseases. Patients with glomerular disease on immunosuppressive drugs may be more prone to infections. In some patients with glomerular illness, the specialists change their immunosuppressive drugs based on their risk of developing end-stage kidney disease and the local transmission of COVID-19. Furthermore, glomerular lesions were witnessed in a minority of patients with COVID-19, that collapse focal segmental glomerulosclerosis (FSGS), also called COVID-associated nephropathy (COVAN).
Therefore, it has been found that the COVID-19 virus is having a major impact on the kidney of patients, which in turn, is projected to upsurge the burden of kidney disorders in the near future and boost the market growth. Thus, overall, COVID-19 had a major impact on the global nephritis market.
Global Nephritis Market Scope
The global nephritis market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Goodpasture Syndrome
- ACE Inhibitors
- Immunosuppressive Therapy
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Nephritis Market Regional Analysis/Insights
The global nephritis market is analyzed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global nephritis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Europe has witnessed the highest growth for global nephritis market throughout the forecasted period due to the high diagnostic rate and presence of key players in this region.
North America dominates the market due to the growing cases of kidney disorder, presence of sophisticated medical facilities to maximize the treatment effectiveness for patients suffering from glomerular disease and increases focuses in the research and development activity.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Nephritis Market Share Analysis
The global nephritis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global nephritis market.
Key players operating in the global nephritis market include:
- Pfizer Inc (U.S.)
- AstraZeneca (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Abbvie,Inc (U.S.)
- Dr. Reddy's Laboratories Ltd (India)
- Endo International plc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Sun Pharmaceutical Industries Ltd (India)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Lupin (India)
- Cipla Inc (India)
- Aurobindo Pharma (India)
- Fresenius SE & Co. KGaA (Germany)
- Sanofi (France)
- Takeda Pharmaceutical Company Limited (Japan)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)